SciVision Biotech Inc.

Taiwan Stock Exchange 1786.TW

SciVision Biotech Inc. Operating Income for the year ending December 31, 2023: USD 6.50 M

SciVision Biotech Inc. Operating Income is USD 6.50 M for the year ending December 31, 2023, a 13.12% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

SciVision Biotech Inc. Operating Income for the year ending December 31, 2022 was USD 5.75 M, a 28.26% change year over year.
SciVision Biotech Inc. Operating Income for the year ending December 31, 2021 was USD 4.48 M, a -22.13% change year over year.
SciVision Biotech Inc. Operating Income for the year ending December 31, 2020 was USD 5.76 M, a 22.39% change year over year.
SciVision Biotech Inc. Operating Income for the year ending December 31, 2019 was USD 4.70 M, a 78.30% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Taiwan Stock Exchange: 1786.TW

SciVision Biotech Inc.

CEO	Tai Xian Han
IPO Date	March 12, 2013
Location	Taiwan
Headquarters	1, South 1st Road
Employees	64
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Cosmetics

Description

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.

Key trends

Past 5 years